EurekAlert! -
17 Nov 2014 07:00
(Mayo Clinic) The investigational drug ixazomib taken orally in combination with lenalidomide and dexamethasone shows promise in patients with newly diagnosed multiple myeloma, according to the results of a phase 1/2 study published in the journal Lancet Oncology.
Share this Article